公开(公告)号：US11965032B1

公开(公告)日：2024-04-23

申请号：US18167631

申请日：2023-02-10

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

公开(公告)号：US20220143026A1

公开(公告)日：2022-05-12

申请号：US17525731

申请日：2021-11-12

Applicant: TG Therapeutics, Inc. ,  Rhizen Pharmaceuticals SA ,  LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Inventor： Michael S. WEISS ,  Hari P. MISKIN ,  Peter SPORTELLI

IPC: A61K31/519 ,  A61K39/395 ,  A61K31/5025 ,  C07K16/28 ,  A61K45/06 ,  A61P35/00

Abstract: Methods for treating B-cell malignancies are provided comprising administering a triple combination of agents, comprising: (i) a PI3K-delta selective inhibitor (e.g., umbralisib); (ii) an anti-CD20 antibody (e.g., ublituximab); and (iii) the Bruton's tyrosine kinase (BTK) inhibitor TG-1701. Kits for carrying out the claimed methods are also provided.

公开(公告)号：US20190175592A1

公开(公告)日：2019-06-13

申请号：US16304590

申请日：2017-05-26

Applicant: TG THERAPEUTICS, INC. ,  RHIZEN PHARMACEUTICALS SA ,  LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Inventor： Michael S. WEISS ,  Hari P. MISKIN ,  Peter SPORTLLI

IPC: A61K31/4985 ,  A61K31/4155 ,  A61P35/02 ,  A61K31/416 ,  A61K31/506 ,  A61K31/519 ,  C07K16/28 ,  A61K9/00

Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.

公开(公告)号：US20240209110A1

公开(公告)日：2024-06-27

申请号：US18597711

申请日：2024-03-06

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

公开(公告)号：US11884740B1

公开(公告)日：2024-01-30

申请号：US17892407

申请日：2022-08-22

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  C07K2317/732 ,  C07K2317/734

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

公开(公告)号：US10966977B2

公开(公告)日：2021-04-06

申请号：US16304590

申请日：2017-05-26

Applicant: TG Therapeutics, Inc. ,  Rhizen Pharmaceuticals SA ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： Michael S. Weiss ,  Hari P. Miskin ,  Peter Sportelli

IPC: A61K31/4985 ,  C07K16/28 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61K39/395 ,  A61P35/02 ,  A61K9/00 ,  A61K31/4155 ,  A61K31/416

Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.

公开(公告)号：US20200323981A1

公开(公告)日：2020-10-15

申请号：US16946585

申请日：2020-06-29

Applicant: TG Therapeutics, Inc. ,  Rhizen Pharmaceuticals SA ,  Laboratoire Francais du Fractionnement et des Biotechnologies

Inventor： Michael S. Weiss ,  Hari P. Miskin ,  Peter Sportelli ,  Swaroop K.V.S. Vakkalanka

IPC: A61K39/395 ,  A61K31/519 ,  A61K45/06 ,  C07K16/28

Abstract: Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provides for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma. The invention also provides for a combination of a compound of formula A, or stereoisomers thereof, and anti-CD20 antibodies, including ublituximab for the treatment and/or amelioration of multiple scelrosis.

公开(公告)号：US11807689B1

公开(公告)日：2023-11-07

申请号：US17892465

申请日：2022-08-22

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K47/02

CPC classification number: C07K16/2887 ,  A61K47/02 ,  C07K2317/732 ,  C07K2317/734

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

公开(公告)号：US10729768B2

公开(公告)日：2020-08-04

申请号：US15635733

申请日：2017-06-28

Applicant: TG Therapeutics, Inc. ,  Rhizen Pharmaceuticals SA ,  Laboratoire Francais du Fractionnement et des Biotechnologies

Inventor： Michael S. Weiss ,  Hari P. Miskin ,  Peter Sportelli ,  Swaroop K. V. S. Vakkalanka

IPC: A61K39/395 ,  A61K31/519 ,  C07K16/28 ,  A61K45/06

Abstract: Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

公开(公告)号：US20190247399A1

公开(公告)日：2019-08-15

申请号：US16331407

申请日：2017-09-08

Applicant: TG Therapeutics, Inc. ,  Rhizen Pharmaceuticals SA ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： Michael S. Weiss ,  Hari P. Miskin ,  Peter Sportelli

IPC: A61K31/519 ,  A61P35/02 ,  C07K16/28 ,  A61K9/00

CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K9/0053 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2300/00

Abstract: The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI3 kinase (PI3K)-delta (e.g., TGR-1202); (ii) at least one anti-CD20 antibody (e.g., ublituximab); and (iii) at least one anti-PD-1 antibody (e.g., pembrolizumab) or anti-PD-Ll antibody (e.g., atezolizumab). Treatment regimens are also provided.